Cargando…

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients

INTRODUCTION: Protein expression is deregulated in cancer, and the proteomic changes observed in lung cancer may be a consequence of mutations in essential genes. The purpose of this study was to identify protein expression associated with prognosis in lung cancers stratified by smoking status, mole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halvorsen, Ann Rita, Haugen, Mads Haugland, Öjlert, Åsa Kristina, Lund-Iversen, Marius, Jørgensen, Lars, Solberg, Steinar, Mælandsmo, Gunhild M., Brustugun, Odd Terje, Helland, Åslaug
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725872/ https://www.ncbi.nlm.nih.gov/pubmed/33324562 http://dx.doi.org/10.3389/fonc.2020.590755

Ejemplares similares

The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
por: Öjlert, Åsa Kristina, et al.
Publicado: (2019)

Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
por: Halvorsen, Ann Rita, et al.
Publicado: (2019)

Osteopontin is a prognostic biomarker in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2013)

Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2016)

Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
por: Nordgård, Oddmund, et al.
Publicado: (2013)

Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2012)

NUT expression in primary lung tumours
por: Lund-Iversen, Marius, et al.
Publicado: (2015)

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2021)

Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
por: Haakensen, Vilde D., et al.
Publicado: (2020)

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
por: Berg, Janna, et al.
Publicado: (2018)

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes
por: Eide, Hanne A., et al.
Publicado: (2016)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
por: Turzer, Martin, et al.
Publicado: (2010)

Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
por: Nilssen, Yngvar, et al.
Publicado: (2023)

Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity
por: Turzer, Martin, et al.
Publicado: (2011)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
por: Berg, Janna, et al.
Publicado: (2021)

Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
por: Öjlert, Åsa Kristina, et al.
Publicado: (2021)

Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
por: Eide, Hanne Astrid, et al.
Publicado: (2016)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
por: Joly-Battaglini, Albane, et al.
Publicado: (2016)

The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
por: Frafjord, Astri, et al.
Publicado: (2021)

A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
por: Halvorsen, Ann Rita, et al.
Publicado: (2016)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
por: Eide, Hanne A., et al.
Publicado: (2018)

miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
por: Normann, Lisa Svartdal, et al.
Publicado: (2022)

Nuclear Legumain Activity in Colorectal Cancer
por: Haugen, Mads H., et al.
Publicado: (2013)

Correction: Nuclear Legumain Activity in Colorectal Cancer
por: Haugen, Mads H., et al.
Publicado: (2013)

A NOTCH added to metabolomics
por: Brustugun, Odd Terje
Publicado: (2019)

High number of kinome‐mutations in non‐small cell lung cancer is associated with reduced immune response and poor relapse‐free survival
por: Helland, Å., et al.
Publicado: (2017)

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
por: Horndalsveen, Henrik, et al.
Publicado: (2022)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

Cystatin E/M suppresses legumain activity and invasion of human melanoma
por: Briggs, Jon J, et al.
Publicado: (2010)

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
por: Normann, Lisa Svartdal, et al.
Publicado: (2021)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2022)

AXL inhibition improves BRAF-targeted treatment in melanoma
por: Nyakas, Marta, et al.
Publicado: (2022)

“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”
por: Dyrbekk, Anne Pernille Harlem, et al.
Publicado: (2023)

Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
por: Tamhane, Tripti, et al.
Publicado: (2015)

Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway
por: Børø, Siri, et al.
Publicado: (2022)

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
por: Normann, Lisa Svartdal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m3un7ekqt510jfvbalgcejih7e